ALKS (Alkermes Inc. plc)
Insider Trading Activity
Every open-market purchase and sale reported by ALKS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-03 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | — | — |
| 2026-08-03 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | — | — |
| 2026-08-03 | nancy lynn MD snyderman | Director | MIXED | — | — |
| 2026-07-06 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | — | — |
| 2026-07-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | — | — |
| 2026-06-12 | Christopher I Wright | Director | Sell | — | — |
| 2026-06-04 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | — | — |
| 2026-06-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | — | — |
| 2026-05-29 | Samuel Joseph Parisi | VP, Finance (Interim PAO) | MIXED | — | — |
| 2026-05-22 | Shane Cooke | Director | A | — | — |
| 2026-05-22 | Shane Cooke | Director | MIXED | — | — |
| 2026-05-22 | Frank Anders Wilson | Director | MIXED | — | — |
| 2026-05-22 | BRIAN P MCKEON | Director | MIXED | — | — |
| 2026-05-22 | nancy lynn MD snyderman | Director | MIXED | — | — |
| 2026-05-22 | RICHARD GAYNOR | Director | A | — | — |
| 2026-05-22 | RICHARD GAYNOR | Director | MIXED | — | — |
| 2026-05-22 | Nancy Lurker | Director | MIXED | — | — |
| 2026-05-22 | CATO T LAURENCIN | Director | MIXED | — | — |
| 2026-05-22 | Christopher I Wright | Director | MIXED | — | — |
| 2026-05-04 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | — | — |
| 2026-05-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | — | — |
| 2026-04-13 | Nancy Lurker | Director | MIXED | — | — |
| 2026-04-06 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | — | — |
| 2026-04-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | — | — |
| 2026-03-04 | RICHARD F POPS | Director and CEO, Alkermes plc | A | — | — |
| 2026-03-04 | Blair Curtis Jackson | EVP, Chief Operating Officer | A | — | — |
| 2026-03-04 | Samuel Joseph Parisi | VP, Finance (Interim PAO) | Sell | — | — |
| 2026-03-04 | Christian Todd Nichols | SVP, Chief Commercial Officer | Sell | — | — |
| 2026-03-04 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | — | — |
| 2026-03-04 | Joshua Reed | SVP, Chief Financial Officer | A | — | — |
| 2026-03-04 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | — | — |
| 2026-02-27 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | — | — |
| 2026-02-27 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | MIXED | — | — |
| 2026-02-27 | Samuel Joseph Parisi | VP, Finance (Interim PAO) | MIXED | — | — |
| 2026-02-27 | Blair Curtis Jackson | EVP, Chief Operating Officer | MIXED | — | — |
| 2026-02-27 | Christian Todd Nichols | SVP, Chief Commercial Officer | MIXED | — | — |
| 2026-02-25 | Samuel Joseph Parisi | VP, Finance (Interim PAO) | MIXED | — | — |
| 2026-02-25 | Christian Todd Nichols | SVP, Chief Commercial Officer | MIXED | — | — |
| 2026-02-25 | Blair Curtis Jackson | EVP, Chief Operating Officer | MIXED | — | — |
| 2026-02-25 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | — | — |
| 2026-02-25 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | MIXED | — | — |
| 2026-02-20 | Samuel Joseph Parisi | VP, Finance (Interim PAO) | MIXED | — | — |
| 2026-02-20 | Christian Todd Nichols | SVP, Chief Commercial Officer | MIXED | — | — |
| 2026-02-20 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | MIXED | — | — |
| 2026-02-20 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | — | — |
| 2026-02-20 | Blair Curtis Jackson | EVP, Chief Operating Officer | MIXED | — | — |
| 2026-02-06 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | MIXED | — | — |
| 2026-02-06 | Blair Curtis Jackson | EVP, Chief Operating Officer | MIXED | — | — |
| 2026-02-06 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | — | — |
| 2026-02-06 | Christian Todd Nichols | SVP, Chief Commercial Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 7,750,000 | — |
| — | Director and CEO, Alkermes plc | 1,377,740 | — |
| — | Director | 360,600 | — |
| — | SVP, Corp Dev., Alkermes, Inc. | 281,730 | — |
| — | Director | 256,804 | — |
| — | EVP, Chief Operating Officer | 245,003 | — |
| — | SVP, Alks Inc; CFO ALKS | 241,828 | — |
| — | EVP, CLO, Alkermes, Inc. | 225,456 | — |
| — | SVP, Chief Financial Officer | 150,690 | — |
| — | SVP, Chief Commercial Officer | 109,769 | — |
| — | Director | 107,780 | — |
| — | Director | 106,679 | — |
| — | President & CEO | 106,616 | — |
| — | Director | 84,905 | — |
| — | SVP, COO & CRO, Alkermes, Inc. | 71,342 | — |
| — | EVP/CAO/CCO/CRO Alks Inc; | 70,612 | — |
| — | EVP R&D, Chief Medical Officer | 69,389 | — |
| — | EVP, R&D & CMO, Alkermes, Inc. | 58,821 | — |
| — | Director | 53,124 | — |
| — | SVP/Chief Comm Off, Alks Inc | 49,503 | — |
| — | Director | 48,536 | — |
| — | Director | 37,226 | — |
| — | Director | 36,178 | — |
| — | Director | 35,751 | — |
| — | Director | 33,769 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALKS quote page; the site-wide leaderboard is on the insider transactions hub.